The award, from NIH’s National Center for Advancing Translational Sciences (NCATS), supports the Division of Pre-Clinical Innovation’s (DPI) drug development programs.
“The goal of the DPI is to advance collaborative research projects across pre-clinical phases of the translational science spectrum,” Chris Conway, senior vice president, discovery, development and analytical services at AMRI told Outsourcing-Pharma.com.
The global contract research and manufacturing organization (CRO) will provide services related to process development, analytical development and small-scale GMP manufacture of small molecule drug candidates for preclinical trials.
Conway explained task order requests for proposals will be circulated amongst all contractors under a particular technical area each time new work is needed.
Investment in additional capacity is not anticipated at this point in time, he said.
“The contract emphasizes our long-term relationship with the NIH – we’ve been working with the NIH for years with great success, and we are proud that our relationship with the NIH has grown and matured,” added Conway.